Loading
Life sciences · Journal article
Molecular Pharmaceutics · October 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Non-invasive identification of epidermal growth factor receptor (EGFR) mutation status remains a critical unmet clinical need for personalized therapy of non-small-cell lung cancer (NSCLC). Given that CD38 is markedly downregulated in EGFR-mutant NSCLC while remaining highly expressed in EGFR-wild-type tumors, CD38 can serve as a surrogate imaging biomarker for the indirect stratification of EGFR molecular phenotypes. Herein, we report the preclinical development and comprehensive characterization of 18F-NOTA-78c, a novel 18F-radiolabeled small-molecule PET imaging probe targeting CD38. 18F-NOTA-78c was synthesized under mild aqueous conditions with high radiochemical purity (>95%). The tracer exhibited favorable in vitro and in vivo stability, high hydrophilicity (logD7.4 = −1.76 ± 0.02), and specific CD38-mediated cellular binding, with the cold precursor showing an IC50 value of 38.27 nM. In vivo micro-PET/CT and biodistribution studies in NSCLC xenograft-bearing mice demonstrated higher tracer accumulation in EGFR wild-type A549 tumors (SUVmax = 1.28, T/M = 4.74), whereas low uptake was observed in EGFR-mutant HCC827 and H1975 tumors. Our findings validate the proof-of-concept application of CD38-targeted PET for indirect EGFR status differentiation in NSCLC.